Eli Lilly's tirzepatide franchise (Mounjaro/Zepbound) continues to take share from Novo Nordisk as supply normalizes and oral GLP-1 orforglipron approaches a 2026 launch. Donanemab in Alzheimer's is ramping. Manufacturing capacity additions in Indiana, North Carolina, and Ireland resolve the supply constraints that capped 2024-2025 growth. Pipeline depth (retatrutide, oral SMA) underappreciated.
Signals scoped to US · Company-specific tagging coming soon.